OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy
OcuTerra Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
OcuTerra Therapeutics Announces Last Patient Completes Final Visit in Nesvategrast (OTT166) Eye Drop Phase 2 DR:EAM Clinical Trial in Diabetic Retinopathy
OcuTerra President and CEO Kerrie Brady Named to 2023 PharmaVoice 100 List of Most Inspiring Leaders
OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy
OcuTerra Appoints Bill Steinkrauss as Chief Financial Officer
OcuTerra to Participate in Upcoming Investor Conferences
OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease
OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathy
OcuTerra Appoints Majid Anderesi, MD, as Vice President of Clinical and Medical Affairs
OcuTerra Appoints Barbara Ryan to Board of Directors
OcuTerra Raises $35 Million Series B Financing
OcuTerra Appoints Richard Lindstrom, MD, and Sheri Rowen, MD, to Scientific Advisory Board
OcuTerra Appoints David J. Tanzer, MD, as Chief Medical Officer
OcuTerra Strengthens Board of Directors with Three New Key Appointments
